36 results on '"Bifulco, Katia"'
Search Results
2. Data from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency
- Author
-
Carriero, Maria Vincenza, primary, Bifulco, Katia, primary, Minopoli, Michele, primary, Lista, Liliana, primary, Maglio, Ornella, primary, Mele, Luigi, primary, Di Carluccio, Gioconda, primary, De Rosa, Mario, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
3. Supplementary Figure 1 from A Urokinase Receptor–Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting
- Author
-
Bifulco, Katia, primary, Longanesi-Cattani, Immacolata, primary, Liguori, Eleonora, primary, Arra, Claudio, primary, Rea, Domenica, primary, Masucci, Maria Teresa, primary, De Rosa, Mario, primary, Pavone, Vincenzo, primary, Stoppelli, Maria Patrizia, primary, and Carriero, Maria Vincenza, primary
- Published
- 2023
- Full Text
- View/download PDF
4. Supplementary Methods, Figure Legends, Tables 1 - 4, Figure 1 from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency
- Author
-
Carriero, Maria Vincenza, primary, Bifulco, Katia, primary, Minopoli, Michele, primary, Lista, Liliana, primary, Maglio, Ornella, primary, Mele, Luigi, primary, Di Carluccio, Gioconda, primary, De Rosa, Mario, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
5. Data from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, primary, Bifulco, Katia, primary, Maglio, Ornella, primary, Lista, Liliana, primary, Barbieri, Antonio, primary, Votta, Giuseppina, primary, Masucci, Maria Teresa, primary, Arra, Claudio, primary, Franco, Renato, primary, De Rosa, Mario, primary, Stoppelli, Maria Patrizia, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
6. Video from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, primary, Bifulco, Katia, primary, Maglio, Ornella, primary, Lista, Liliana, primary, Barbieri, Antonio, primary, Votta, Giuseppina, primary, Masucci, Maria Teresa, primary, Arra, Claudio, primary, Franco, Renato, primary, De Rosa, Mario, primary, Stoppelli, Maria Patrizia, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
7. RERF Conformational Preferenc from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, primary, Bifulco, Katia, primary, Maglio, Ornella, primary, Lista, Liliana, primary, Barbieri, Antonio, primary, Votta, Giuseppina, primary, Masucci, Maria Teresa, primary, Arra, Claudio, primary, Franco, Renato, primary, De Rosa, Mario, primary, Stoppelli, Maria Patrizia, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
8. Dattabase Information from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, primary, Bifulco, Katia, primary, Maglio, Ornella, primary, Lista, Liliana, primary, Barbieri, Antonio, primary, Votta, Giuseppina, primary, Masucci, Maria Teresa, primary, Arra, Claudio, primary, Franco, Renato, primary, De Rosa, Mario, primary, Stoppelli, Maria Patrizia, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
9. Supplementary Data to Figure 3 from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, primary, Bifulco, Katia, primary, Maglio, Ornella, primary, Lista, Liliana, primary, Barbieri, Antonio, primary, Votta, Giuseppina, primary, Masucci, Maria Teresa, primary, Arra, Claudio, primary, Franco, Renato, primary, De Rosa, Mario, primary, Stoppelli, Maria Patrizia, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
10. Video Description from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, primary, Bifulco, Katia, primary, Maglio, Ornella, primary, Lista, Liliana, primary, Barbieri, Antonio, primary, Votta, Giuseppina, primary, Masucci, Maria Teresa, primary, Arra, Claudio, primary, Franco, Renato, primary, De Rosa, Mario, primary, Stoppelli, Maria Patrizia, primary, and Pavone, Vincenzo, primary
- Published
- 2023
- Full Text
- View/download PDF
11. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor
- Author
-
Montuori, Nunzia, Bifulco, Katia, Carriero, Maria Vincenza, La Penna, Claudio, Visconte, Valeria, Alfano, Daniela, Pesapane, Ada, Rossi, Francesca Wanda, Salzano, Salvatore, Rossi, Guido, and Ragno, Pia
- Published
- 2011
- Full Text
- View/download PDF
12. Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells
- Author
-
Baroni, Adone, Donnarumma, Giovanna, Paoletti, Iole, Longanesi-Cattani, Immacolata, Bifulco, Katia, Tufano, Maria Antonietta, and Carriero, Maria Vincenza
- Published
- 2009
- Full Text
- View/download PDF
13. Melanoma and immunotherapy bridge 2015
- Author
-
Nanda, Vashisht G. Y., Peng, Weiyi, Hwu, Patrick, Davies, Michael A., Ciliberto, Gennaro, Fattore, Luigi, Malpicci, Debora, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Croce, Carlo M., Mancini, Rita, Spranger, Stefani, Gajewski, Thomas F., Wang, Yangyang, Ferrone, Soldano, Vanpouille-Box, Claire, Wennerberg, Erik, Pilones, Karsten A., Formenti, Silvia C., Demaria, Sandra, Tang, Haidong, Wang, Yang, Fu, Yang-Xin, Dummer, Reinhard, Puzanov, Igor, Tarhini, Ahmad, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sanders, Cindy, Kirkwood, John M., Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J., Zarour, Hassane M., Stroncek, David F., Huber, Veronica, Rivoltini, Licia, Thurin, Magdalena, Rau, Tilman, Lugli, Alessandro, Pagès, Franck, Camarero, Jorge, Sancho, Arantxa, Jommi, Claudio, de Coaña, Yago Pico, Wolodarski, Maria, Yoshimoto, Yuya, Gentilcore, Giusy, Poschke, Isabel, Masucci, Giuseppe V., Hansson, Johan, Kiessling, Rolf, Scognamiglio, Giosuè, Sabbatino, Francesco, Marino, Federica Zito, Anniciello, Anna Maria, Cantile, Monica, Cerrone, Margherita, Scala, Stefania, D’alterio, Crescenzo, Ianaro, Angela, Cirin, Giuseppe, Liguori, Giuseppina, Bott, Gerardo, Chapman, Paul B., Robert, Caroline, Larkin, James, Haanen, John B., Ribas, Antoni, Hogg, David, Hamid, Omid, Testori, Alessandro, Lorigan, Paul, Sosman, Jeffrey A., Flaherty, Keith T., Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, McArthur, Grant A., Sznol, Mario, Callahan, Margaret K., Kluger, Harriet, Postow, Michael A., Gordan, RuthAnn, Segal, Neil H., Rizvi, Naiyer A., Lesokhin, Alexander, Atkins, Michael B., Burke, Matthew M., Ralabate, Amanda, Rivera, Angel, Kronenberg, Stephanie A., Agunwamba, Blessing, Ruisi, Mary, Horak, Christine, Jiang, Joel, Wolchok, Jedd, Ascierto, Paolo A., Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stoyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Chang, Ilsung, Koralek, Daniel O., Rooney, Isabelle, Yan, Yibing, Dréno, Brigitte, Sullivan, Ryan, Patel, Manish, Hodi, Stephen, Amaria, Rodabe, Boasberg, Peter, Wallin, Jeffrey, He, Xian, Cha, Edward, Richie, Nicole, Ballinger, Marcus, Smith, David C., Bauer, Todd M., Wasser, Jeffrey S., Luke, Jason J., Balmanoukian, Ani S., Kaufman, David R., Zhao, Yufan, Maleski, Janet, Leopold, Lance, Gangadhar, Tara C., Long, Georgina V., Michielin, Olivier, VanderWalde, Ari, Andtbacka, Robert H. I., Cebon, Jonathan, Fernandez, Eugenio, Malvehy, Josep, Olszanski, Anthony J., Gause, Christine, Chen, Lisa, Chou, Jeffrey, Stephen Hodi, F., Brady, Benjamin, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Lebbé, Celeste, Ny, Lars, Chacon, Matias, Queirolo, Paola, Loquai, Carmen, Cheema, Parneet, Berrocal, Alfonso, Eizmendi, Karmele Mujika, Bar-Sela, Gil, Hardy, Helene, Weber, Jeffrey S., Grob, Jean-Jacques, Marquez-Rodas, Ivan, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Wolchok, Jedd D., Pinto, Rosamaria, De Summa, Simona, Garrisi, Vito Michele, Strippoli, Sabino, Azzariti, Amalia, Guida, Gabriella, Guida, Michele, Tommasi, Stefania, Jacquelot, Nicolas, Enot, David, Flament, Caroline, Pitt, Jonathan M., Vimond, Nadège, Blattner, Carolin, Yamazaki, Takahiro, Roberti, Maria-Paula, Vetizou, Marie, Daillere, Romain, Poirier-Colame, Vichnou, la Semeraro, Michaë, Caignard, Anne, Slingluff, Craig L, Sallusto, Federica, Rusakiewicz, Sylvie, Weide, Benjamin, Marabelle, Aurélien, Kohrt, Holbrook, Dalle, Stéphane, Cavalcanti, Andréa, Kroemer, Guido, Di Giacomo, Anna Maria, Maio, Michaele, Wong, Phillip, Yuan, Jianda, Umansky, Viktor, Eggermont, Alexander, Zitvogel, Laurence, Anna, Passarelli, Marco, Tucci, Stefania, Stucci, Francesco, Mannavola, Mariaelena, Capone, Gabriele, Madonna, Antonio, Ascierto Paolo, Franco, Silvestris, Roberti, María Paula, Enot, David P., Semeraro, Michaela, Jégou, Sarah, Flores, Camila, Kwon, Byoung S., Anderson, Ana Carrizossa, Borg, Christophe, Aubin, François, Ayyoub, Maha, De Presbiteris, Anna Lisa, Cordaro, Fabiola Gilda, Camerlingo, Rosa, Fratangelo, Federica, Mozzillo, Nicola, Pirozzi, Giuseppe, Patriarca, Eduardo J., Caputo, Emilia, Motti, Maria Letizia, Falcon, Rosaria, Miceli, Roberta, Capone, Mariaelena, Madonna, Gabriele, Mallardo, Domenico, Carrier, Maria Vincenza, Panza, Elisabetta, De Cicco, Paola, Armogida, Chiara, Ercolano, Giuseppe, Botti, Gerardo, Cirino, Giuseppe, Sandru, Angela, Blank, Miri, Balatoni, Timea, Olasz, Judit, Farkas, Emil, Szollar, Andras, Savolt, Akos, Godeny, Maria, Csuka, Orsolya, Horvath, Szabolcs, Eles, Klara, Shoenfeld, Yehuda, Kasler, Miklos, Costantini, Susan, Capone, Francesca, Moradi, Farnaz, Berglund, Pontus, Leandersson, Karin, Linnskog, Rickard, Andersson, Tommy, Prasad, Chandra Prakash, Nigro, Cristiana Lo, Lattanzio, Laura, Wang, Hexiao, Proby, Charlotte, Syed, Nelofer, Occelli, Marcella, Cauchi, Carolina, Merlano, Marco, Harwood, Catherine, Thompson, Alastair, Crook, Tim, Bifulco, Katia, Ingangi, Vincenzo, Minopoli, Michele, Ragone, Concetta, Pessi, Antonello, Mannavola, Francesco, D’Oronzo, Stella, Felici, Claudia, Tucci, Marco, Doronzo, Antonio, Silvestris, Franco, Ferretta, Anna, Guida, Stefania, Maida, Imma, Cocco, Tiziana, Passarelli, Anna, Quaresmini, Davide, Franzese, Ornella, Palermo, Belinda, Di Donna, Cosmo, Sperduti, Isabella, Foddai, MariaLaura, Stabile, Helena, Gismondi, Angela, Santoni, Angela, Nisticò, Paola, Sponghini, Andrea P., Platini, Francesca, Marra, Elena, Rondonotti, David, Alabiso, Oscar, Fierro, Maria T., Savoia, Paola, Stratica, Florian, Quaglino, Pietro, Di Monta, Gianluca, Corrado, Caracò, Di Marzo, Massimiliano, Ugo, Marone, Di Cecilia, Maria Luisa, Nicola, Mozzillo, Fusciello, Celeste, Marra, Antonio, Guarrasi, Rosario, Baldi, Carlo, Russo, Rosa, Di Giulio, Giovanni, Faiola, Vincenzo, Zeppa, Pio, Pepe, Stefano, Gambale, Elisabetta, Carella, Consiglia, Di Paolo, Alessandra, De Tursi, Michele, Marra, Laura, De Murtas, Fara, Sorrentino, Valeria, Voinea, Silviu, Panaitescu, Eugenia, Bolovan, Madalina, Stanciu, Adina, Cinca, Sabin, Botti, Chiara, Aquino, Gabriella, Anniciello, Annamaria, Fortes, Cristina, Mastroeni, Simona, Caggiati, Alessio, Passarelli, Francesca, Zappalà, Alba, Capuano, Maria, Bono, Riccardo, Nudo, Maurizio, Marino, Claudia, Michelozzi, Paola, De Biasio, Valeria, Battarra, Vincenzo C., Formenti, Silvia, Ascierto, Maria Libera, McMiller, Tracee L., Berger, Alan E., Danilova, Ludmila, Anders, Robert A., Netto, George J., Xu, Haiying, Pritchard, Theresa S., Fan, Jinshui, Cheadle, Chris, Cope, Leslie, Drake, Charles G., Pardoll, Drew M., Taube, Janis M., Topalian, Suzanne L., Gnjatic, Sacha, Nataraj, Sarah, Imai, Naoko, Rahman, Adeeb, Jungbluth, Achim A., Pan, Linda, Venhaus, Ralph, Park, Andrew, Lehmann, Frédéric F., Lendvai, Nikoletta, Cohen, Adam D., Cho, Hearn J., Daniel, Speiser, and Hirsh, Vera
- Subjects
Medicine(all) ,Biochemistry, Genetics and Molecular Biology(all) ,Meeting Abstracts - Abstract
Table of contents MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh
- Published
- 2016
14. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas
- Author
-
Carriero, Maria Vincenza, primary, Bifulco, Katia, additional, Ingangi, Vincenzo, additional, Costantini, Susan, additional, Botti, Giovanni, additional, Ragone, Concetta, additional, Minopoli, Michele, additional, Motti, Maria Letizia, additional, Rea, Domenica, additional, Scognamiglio, Giosuè, additional, Botti, Gerardo, additional, Arra, Claudio, additional, Ciliberto, Gennaro, additional, and Pessi, Antonello, additional
- Published
- 2017
- Full Text
- View/download PDF
15. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells
- Author
-
Ingangi, Vincenzo, primary, Bifulco, Katia, additional, Yousif, Ali Munaim, additional, Ragone, Concetta, additional, Motti, Maria Letizia, additional, Rea, Domenica, additional, Minopoli, Michele, additional, Botti, Giovanni, additional, Scognamiglio, Giuseppe, additional, Fazioli, Flavio, additional, Gallo, Michele, additional, De Chiara, Annarosaria, additional, Arra, Claudio, additional, Grieco, Paolo, additional, and Carriero, Maria Vincenza, additional
- Published
- 2016
- Full Text
- View/download PDF
16. Studies on some structural proteins during development of chicken inner ear
- Author
-
PISCOPO, MARINA, B. Avallone, BIFULCO, KATIA, U. Fascio, BALSAMO, GIUSEPPE, MARMO, FRANCESCO, Piscopo, Marina, Avallone, Bice, Bifulco, Katia, Fascio, Umberto, Balsamo, Giuseppe, Marmo, Francesco, official organ of the Italian society of Biochemistry and Molecular Biology, biomedia, Avallone, B., and Fascio, U.
- Subjects
inner ear ,chicken ,structural protein - Published
- 2002
17. Studies on some proteins in the early posthatch and developing chick inner ear
- Author
-
AVALLONE, BICE, BALSAMO, GIUSEPPE, BIFULCO, KATIA, MARMO, FRANCESCO, PISCOPO, MARINA, U. Fascio, Avallone, Bice, Balsamo, Giuseppe, Bifulco, Katia, U., Fascio, Marmo, Francesco, and Piscopo, Marina
- Subjects
inner ear ,chick ,tubuline ,actin ,proteins - Published
- 2002
18. Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes
- Author
-
Yousif, Ali Munaim, primary, Minopoli, Michele, additional, Bifulco, Katia, additional, Ingangi, Vincenzo, additional, Di Carluccio, Gioconda, additional, Merlino, Francesco, additional, Motti, Maria Letizia, additional, Grieco, Paolo, additional, and Carriero, Maria Vincenza, additional
- Published
- 2015
- Full Text
- View/download PDF
19. Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
- Author
-
Milone, Maria Rita, primary, Pucci, Biagio, additional, Bifulco, Katia, additional, Iannelli, Federica, additional, Lombardi, Rita, additional, Ciardiello, Chiara, additional, Bruzzese, Francesca, additional, Carriero, Maria Vincenza, additional, and Budillon, Alfredo, additional
- Published
- 2014
- Full Text
- View/download PDF
20. Abstract 5311: Proteomic characterization of zoledronic acid-resistant prostate cancer cells identified key proteins in cytoskeleton organization and cancer stem cell markers associated with a very aggressive phenotype
- Author
-
Milone, Maria Rita, primary, Pucci, Biagio, additional, Iannelli, Federica, additional, Lombardi, Rita, additional, Bifulco, Katia, additional, Bruzzese, Francesca, additional, Gennaro, Elena D., additional, Avallone, Antonio, additional, Carriero, Maria Vincenza, additional, and Budillon, Alfredo, additional
- Published
- 2014
- Full Text
- View/download PDF
21. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence
- Author
-
Bifulco, Katia, primary, Votta, Giuseppina, additional, Ingangi, Vincenzo, additional, Carluccio, Gioconda Di, additional, Rea, Domenica, additional, Losito, Simona, additional, Montuori, Nunzia, additional, Ragno, Pia, additional, Stoppelli, Maria Patrizia, additional, Arra, Claudio, additional, and Carriero, Maria Vincenza, additional
- Published
- 2014
- Full Text
- View/download PDF
22. UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency
- Author
-
Carriero, Maria Vincenza, primary, Bifulco, Katia, additional, Minopoli, Michele, additional, Lista, Liliana, additional, Maglio, Ornella, additional, Mele, Luigi, additional, Di Carluccio, Gioconda, additional, De Rosa, Mario, additional, and Pavone, Vincenzo, additional
- Published
- 2014
- Full Text
- View/download PDF
23. A Urokinase Receptor–Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting
- Author
-
Bifulco, Katia, primary, Longanesi-Cattani, Immacolata, additional, Liguori, Eleonora, additional, Arra, Claudio, additional, Rea, Domenica, additional, Masucci, Maria Teresa, additional, De Rosa, Mario, additional, Pavone, Vincenzo, additional, Stoppelli, Maria Patrizia, additional, and Carriero, Maria Vincenza, additional
- Published
- 2013
- Full Text
- View/download PDF
24. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor
- Author
-
Bifulco, Katia, Longanesi-Cattani, Immacolata, Gargiulo, Lucia, Maglio, Ornella, Cataldi, Mauro, De Rosa, Mario, Stoppelli, Maria Patrizia, Pavone, Vincenzo, and Carriero, Maria Vincenza
- Published
- 2008
- Full Text
- View/download PDF
25. Single Amino Acid Substitutions in the Chemotactic Sequence of Urokinase Receptor Modulate Cell Migration and Invasion
- Author
-
Bifulco, Katia, primary, Longanesi-Cattani, Immacolata, additional, Franco, Paola, additional, Pavone, Vincenzo, additional, Mugione, Pietro, additional, Di Carluccio, Gioconda, additional, Masucci, Maria Teresa, additional, Arra, Claudio, additional, Pirozzi, Giuseppe, additional, Stoppelli, Maria Patrizia, additional, and Carriero, Maria Vincenza, additional
- Published
- 2012
- Full Text
- View/download PDF
26. Involvement of the Soluble Urokinase Receptor in Chondrosarcoma Cell Mobilization
- Author
-
Bifulco, Katia, primary, Longanesi-Cattani, Immacolata, additional, Masucci, Maria Teresa, additional, De Chiara, Annarosaria, additional, Fazioli, Flavio, additional, Di Carluccio, Gioconda, additional, Pirozzi, Giuseppe, additional, Gallo, Michele, additional, La Rocca, Antonello, additional, Apice, Gaetano, additional, Rocco, Gaetano, additional, and Carriero, Maria Vincenza, additional
- Published
- 2011
- Full Text
- View/download PDF
27. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor
- Author
-
Montuori, Nunzia, primary, Bifulco, Katia, additional, Carriero, Maria Vincenza, additional, La Penna, Claudio, additional, Visconte, Valeria, additional, Alfano, Daniela, additional, Pesapane, Ada, additional, Rossi, Francesca Wanda, additional, Salzano, Salvatore, additional, Rossi, Guido, additional, and Ragno, Pia, additional
- Published
- 2010
- Full Text
- View/download PDF
28. Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis
- Author
-
Carriero, Maria Vincenza, primary, Longanesi-Cattani, Immacolata, additional, Bifulco, Katia, additional, Maglio, Ornella, additional, Lista, Liliana, additional, Barbieri, Antonio, additional, Votta, Giuseppina, additional, Masucci, Maria Teresa, additional, Arra, Claudio, additional, Franco, Renato, additional, De Rosa, Mario, additional, Stoppelli, Maria Patrizia, additional, and Pavone, Vincenzo, additional
- Published
- 2009
- Full Text
- View/download PDF
29. Cell Invasiveness in Sarcomas: A Possibly Useful Clinical Correlation
- Author
-
Bifulco, Katia, primary, De Chiara, Annarosaria, additional, Fazioli, Flavio, additional, Longanesi-Cattani, Immacolata, additional, Cantelmo, Anna Rita, additional, Tirino, Virginia, additional, Apice, Gaetano, additional, Rocco, Gaetano, additional, Lombardi, Maria Luisa, additional, and Carriero, Maria Vincenza, additional
- Published
- 2008
- Full Text
- View/download PDF
30. Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide
- Author
-
Gargiulo, Lucia, primary, Longanesi-Cattani, Immacolata, additional, Bifulco, Katia, additional, Franco, Paola, additional, Raiola, Rosanna, additional, Campiglia, Pietro, additional, Grieco, Paolo, additional, Peluso, Gianfranco, additional, Stoppelli, M. Patrizia, additional, and Carriero, Maria V., additional
- Published
- 2005
- Full Text
- View/download PDF
31. Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide.
- Author
-
Gargiul, Lucia, Longanesi-Cattani, Immacolata, Bifulco, Katia, Francol, Paola, Raiola, Rosanna, Campiglia, Pietro, Grieco, Paolo, Peluso, Gianfranco, Stoppelli, M. Patrizia, and Carriero, Maria V.
- Subjects
- *
UROKINASE , *CELL migration , *PROTEOLYSIS , *PROTEOLYTIC enzymes , *VITRONECTIN , *INTEGRINS - Abstract
The urokinase-type plasminogen activator receptor (uPAR) sustains cell migration through its capacity to promote pericellular proteolysis, regulate integrin function, and mediate chemotactic signaling in response to urokinase. We have characterized the early signaling events triggered by the Ser-Arg-Ser-Arg-Tyr (SRSRY) chemotactic uPAR sequence. Cell exposure to SRSRY peptide promotes directional migration on vitronectin-coated filters, regardless of uPAR expression, in a specific and dose-dependent manner, with maximal effect at a concentration level as low as 10 nM. A similar concentration profile is observed in a quantitative analysis of SRSRY-dependent cytoskeletal rearrangements, mostly consisting of filamentous structures localized in a single cell region. SRSRY analogues with alanine substitutions fail to drive F-actin formation and cell migration, indicating a critical role for each amino acid residue. As with ligand-dependent uPAR signaling, SRSRY stimulates protein kinase C activity and results in ERK½ phosphorylation. The involvement of the high affinity N-formyl-Met-Leu-Phe receptor (FPR) in this process is indicated by the finding that 100 nM N-formyl-Met-Leu-Phe inhibits binding of D2D3 to the cell surface, as well as SRSRY-stimulated cell migration and F-actin polarization. Moreover, cell exposure to SRSRY promotes FPR-dependent vitronectin release and increased uPAR·αvβ5 vitronectin receptor physical association, indicating that αvβ5 activity is regulated by the SRSRY uPAR sequence via FPR. Finally, we provide evidence that αvβ5 is required for SRSRY-dependent ERK½ phosphorylation, whereas it is not required for protein kinase C activation. The data indicate that the ability of uPAR to stimulate cell migration and cytoskeletal rearrangements is retained by the SRSRY peptide alone and that it is supported by cross-talk between FPR and αvβ5. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
32. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells
- Author
-
Ali Munaim Yousif, G. Botti, Annarosaria De Chiara, Giuseppe Scognamiglio, Katia Bifulco, Paolo Grieco, Domenica Rea, Michele Minopoli, Maria Letizia Motti, Michele Gallo, Claudio Arra, Maria Vincenza Carriero, Concetta Ragone, Vincenzo Ingangi, Flavio Fazioli, Ingangi, Vincenzo, Bifulco, Katia, Yousif, ALI MUNAIM, Ragone, Concetta, Motti, MARIA LETIZIA, Rea, Domenica, Minopoli, Michele, Botti, Giovanni, Scognamiglio, Giuseppe, Fazioli, Flavio, Gallo, Michele, De Chiara, Annarosaria, Arra, Claudio, Grieco, Paolo, and Carriero, Maria Vincenza
- Subjects
0301 basic medicine ,musculoskeletal diseases ,formyl peptide receptor type 1 ,Angiogenesis ,Mice, Nude ,Bone Neoplasms ,Peptides, Cyclic ,Receptors, Urokinase Plasminogen Activator ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,osteosarcoma ,urokinase receptor ,Medicine ,Animals ,Humans ,Neoplasm Invasiveness ,Receptor ,chondrosarcoma ,Formyl peptide receptor ,Neovascularization, Pathologic ,business.industry ,Intravasation ,Cell migration ,medicine.disease ,Receptors, Formyl Peptide ,peptide ,Urokinase receptor ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,Cancer research ,peptides ,Osteosarcoma ,Female ,Chondrosarcoma ,business ,Research Paper - Abstract
// Vincenzo Ingangi 1, 2 , Katia Bifulco 1 , Ali Munaim Yousif 3 , Concetta Ragone 1, 2 , Maria Letizia Motti 4 , Domenica Rea 5 , Michele Minopoli 1 , Giovanni Botti 1 , Giuseppe Scognamiglio 6 , Flavio Fazioli 7 , Michele Gallo 7 , Annarosaria De Chiara 6 , Claudio Arra 5 , Paolo Grieco 3 , Maria Vincenza Carriero 1 1 Neoplastic Progression Unit, Department of Experimental Oncology, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy 2 SUN Second University of Naples, Naples, Italy 3 Department of Pharmacy, University Federico II, Naples, Italy 4 University ‘Parthenope’, Naples, Italy 5 Animal Facility, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy 6 Pathology Unit, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy 7 Surgery Unit, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy Correspondence to: Maria Vincenza Carriero, email: mariolinacarriero@yahoo.it , m.carriero@istitutotumori.na.it Keywords: urokinase receptor, formyl peptide receptor type 1, osteosarcoma, chondrosarcoma, peptides Received: April 18, 2016 Accepted: May 20, 2016 Published: June 13, 2016 ABSTRACT The receptor for the urokinase-type plasminogen activator (uPAR) is a widely recognized master regulator of cell migration and uPAR 88–92 is the minimal sequence required to induce cell motility and angiogenesis by interacting with the formyl peptide receptor type 1 (FPR1). In this study, we present evidence that the cyclization of the uPAR 88–92 sequence generates a new potent inhibitor of migration, and extracellular matrix invasion of human osteosarcoma and chondrosarcoma cells expressing comparable levels of FPR1 on cell surface. In vitro , the cyclized peptide [SRSRY] prevents formation of capillary-like tubes by endothelial cells co-cultured with chondrosarcoma cells and trans-endothelial migration of osteosarcoma and chondrosarcoma cells. When chondrosarcoma cells were subcutaneously injected in nude mice, tumor size, intra-tumoral microvessel density and circulating tumor cells in blood samples collected before the sacrifice, were significantly reduced in animals treated daily with i.p-administration of 6 mg/Kg [SRSRY] as compared to animals treated with vehicle only. Our findings indicate that [SRSRY] prevents three key events occurring during the metastatic process of osteosarcoma and chondrosarcoma cells: the extracellular matrix invasion, the formation of a capillary network and the entry into bloodstream.
- Published
- 2016
33. UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency
- Author
-
Michele Minopoli, Mario De Rosa, Katia Bifulco, Luca Lista, Gioconda Di Carluccio, Luigi Mele, Maria Vincenza Carriero, Ornella Maglio, Vincenzo Pavone, Carriero, Maria Vincenza, Bifulco, Katia, Minopoli, Michele, Lista, Liliana, Maglio, Ornella, Mele, Luigi, Di Carluccio, Gioconda, De Rosa, Mario, Pavone, Vincenzo, Carriero, Mv, Bifulco, K, Minopoli, M, Lista, L, Maglio, O, Mele, L, Di Carluccio, G, DE ROSA, Mario, and Pavone, V.
- Subjects
Male ,Models, Molecular ,Vascular Endothelial Growth Factor A ,Cancer Research ,Angiogenesis ,Molecular Conformation ,Angiogenesis Inhibitors ,Rabbit ,LINEAR OLIGOPEPTIDE ,DEFICIENT MICE ,Neovascularization ,Mice ,Drug Stability ,Cell Movement ,Phosphorylation ,CANCER ,MIGRATION ,Cytoskeleton ,Tube formation ,Endothelial Cell ,ALPHA-AMINO-ACIDS ,Cell biology ,Endothelial stem cell ,Vascular endothelial growth factor A ,Oncology ,Biochemistry ,Peptide ,Oligopeptide ,Female ,Rabbits ,medicine.symptom ,Oligopeptides ,Angiogenesis Inhibitor ,Human ,Protein Binding ,THERAPEUTIC PEPTIDES ,Neovascularization, Physiologic ,Biology ,Binding, Competitive ,Cell Line ,In vivo ,medicine ,Animals ,Humans ,PLASMINOGEN-ACTIVATOR ,Nuclear Magnetic Resonance, Biomolecular ,Matrigel ,Animal ,Endothelial Cells ,Receptors, Formyl Peptide ,Urokinase receptor ,UPA ,Peptides - Abstract
This work is based on previous evidence showing that chemotactic sequence of the urokinase receptor (uPAR88-92) drives angiogenesis in vitro and in vivo in a protease-independent manner, and that the peptide Ac-Arg-Glu-Arg-Phe-NH2 (RERF) prevents both uPAR88–92- and VEGF-induced angiogenesis. New N-acetylated and C-amidated peptide analogues containing α-methyl α-amino acids were designed and synthesized to optimize the biochemical properties for therapeutic applications. Among these, Ac-L-Arg-Aib-L-Arg-D-Cα(Me)Phe-NH2, named UPARANT, adopts in solution a turned conformation similar to that found for RERF, is stable to sterilization in 3 mg/mL sealed vials in autoclave for 20 minutes at 120°C, is stable in blood, and displays a long-time resistance to enzymatic proteolysis. UPARANT competes with N-formyl-Met-Leu-Phe (fMLF) for binding to the formyl-peptide receptor, inhibits VEGF-directed endothelial cell migration, and prevents cytoskeletal organization and αvβ3 activation in endothelial cells exposed to VEGF. In vitro, UPARANT inhibits VEGF-dependent tube formation of endothelial cells at a 100× lower concentration than RERF. In vivo, UPARANT reduces to the basal level VEGF-dependent capillary sprouts originating from the host vessels that invaded Matrigel sponges implanted in mice, and completely prevents neovascularization induced by subcorneal implantation of pellets containing VEGF in rabbits. Both excellent stability and potency position UPARANT as a promising new therapeutic agent for the control of diseases fueled by excessive angiogenesis, such as cancer and inflammation. Mol Cancer Ther; 13(5); 1092–104. ©2014 AACR.
- Published
- 2014
34. Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes
- Author
-
Gioconda Di Carluccio, Katia Bifulco, Michele Minopoli, Francesco Merlino, Paolo Grieco, Ali Munaim Yousif, Vincenzo Ingangi, Maria Letizia Motti, Maria Vincenza Carriero, Yousif, ALI MUNAIM, Minopoli, Michele, Bifulco, Katia, Ingangi, Vincenzo, Di Carluccio, Gioconda, Merlino, Francesco, Motti, MARIA LETIZIA, Grieco, Paolo, and Carriero, Maria Vincenza
- Subjects
Macrophage ,media_common.quotation_subject ,lcsh:Medicine ,Biology ,Monocyte ,Monocytes ,Cell Line ,Receptors, Urokinase Plasminogen Activator ,Cell Line, Tumor ,medicine ,Animals ,Amino Acid Sequence ,lcsh:Science ,Receptor ,Internalization ,Peptide sequence ,Chromatography, High Pressure Liquid ,media_common ,Biochemistry, Genetics and Molecular Biology (all) ,Multidisciplinary ,Formyl peptide receptor ,Animal ,Medicine (all) ,Macrophages ,lcsh:R ,Transendothelial and Transepithelial Migration ,Chemotaxis ,Cell migration ,Molecular biology ,Rats ,Urokinase receptor ,medicine.anatomical_structure ,Agricultural and Biological Sciences (all) ,Cyclization ,Peptide ,Rat ,lcsh:Q ,Peptides ,Protein Binding ,Research Article - Abstract
The receptor for the urokinase-type plasminogen activator (uPAR) is a widely recognized master regulator of cell migration and uPAR88-92 is the minimal sequence required to induce cell motility. We and others have previously documented that the uPAR88-92 sequence, even in the form of synthetic linear peptide (SRSRY), interacts with the formyl peptide receptor type 1 (FPR1), henceforth inducing cell migration of several cell lines, including monocytes. FPR1 is mainly expressed by mammalian phagocytic leukocytes and plays a crucial role in chemotaxis. In this study, we present evidence that the cyclization of the SRSRY sequence generates a new potent and stable inhibitor of monocyte trafficking. In rat basophilic leukaemia RBL-2H3/ETFR cells expressing high levels of constitutively activated FPR1, the cyclic SRSRY peptide ([SRSRY]) blocks FPR1 mediated cell migration by interfering with both internalization and ligand-uptake of FPR1. Similarly to RBL-2H3/ETFR cells, [SRSRY] competes with fMLF for binding to FPR1 and prevents agonist-induced FPR1 internalization in human monocyte THP-1 cells. Unlike scramble [RSSYR], [SRSRY] inhibits fMLF-directed migration of monocytes in a dose-dependent manner, with IC50 value of 0.01 nM. PMA-differentiated THP-1 cell exposure to fMLF gradient causes a marked cytoskeletal re-organization with the formation of F-actin rich pseudopodia that are prevented by the addition of [SRSRY]. Furthermore, [SRSRY] prevents migration of human primary monocytes and trans-endothelial migration of monocytes. Our findings indicate that [SRSRY] is a new FPR1 inhibitor which may suggest the development of new drugs for treating pathological conditions sustained by increased motility of monocytes, such as chronic inflammatory diseases.
- Published
- 2015
35. Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.
- Author
-
Milone MR, Pucci B, Bifulco K, Iannelli F, Lombardi R, Ciardiello C, Bruzzese F, Carriero MV, and Budillon A
- Subjects
- Blotting, Western, Cell Movement, Cell Proliferation, Electrophoresis, Gel, Two-Dimensional, Gene Ontology, Gene Regulatory Networks, Humans, Male, Neoplasm Invasiveness, Prostatic Neoplasms drug therapy, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Tumor Cells, Cultured, Zoledronic Acid, Bone Density Conservation Agents pharmacology, Diphosphonates pharmacology, Drug Resistance, Neoplasm, Imidazoles pharmacology, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Proteomics methods, Signal Transduction drug effects
- Abstract
Proteomic analysis identified differentially expressed proteins between zoledronic acid-resistant and aggressive DU145R80 prostate cancer (PCa) cells and their parental DU145 cells. Ingenuity Pathway Analysis (IPA) showed a strong relationship between the identified proteins within a network associated with cancer and with homogeneous cellular functions prevalently related with regulation of cell organization, movement and consistent with the smaller and reduced cell-cell contact morphology of DU145R80 cells. The identified proteins correlated in publically available human PCa genomic data with increased tumor expression and aggressiveness. DU145R80 exhibit also a clear increase of alpha-v-(αv) integrin, and of urokinase receptor (uPAR), both included within the same network of the identified proteins. Interestingly, the actin-rich structures localized at the cell periphery of DU145R80 cells are rich of Filamin A, one of the identified proteins and uPAR which, in turn, co-localizes with αv-integrin, in podosomes and/or invadopodia. Notably, the invasive feature of DU145R80 may be prevented by blocking anti-αv antibody. Overall, we unveil a signaling network that physically links the interior of the nucleus via the cytoskeleton to the extracellular matrix and that could dictate PCa aggressiveness suggesting novel potential prognostic markers and therapeutic targets for PCa patients.
- Published
- 2015
- Full Text
- View/download PDF
36. Structure, function and antagonists of urokinase-type plasminogen activator.
- Author
-
Vincenza Carriero M, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, Mancini A, Caputi M, and Stoppelli MP
- Subjects
- Catalytic Domain, Enzyme Inhibitors pharmacology, Humans, Kringles, Models, Molecular, Protein Conformation, Structure-Activity Relationship, Urokinase-Type Plasminogen Activator antagonists & inhibitors, Urokinase-Type Plasminogen Activator chemistry, Urokinase-Type Plasminogen Activator metabolism
- Abstract
Urokinase (uPA) is a serine protease which converts plasminogen to plasmin, a broad-spectrum protease active on extracellular matrix (ECM) components. Like many components of the blood coagulation, fibrinolytic and complement cascades, uPA has a modular structure, including three conserved domains: a growth factor-like domain (GFD, residues 1 - 49), a kringle domain (residues 50 - 131), linked by an interdomain linker or "connecting peptide" (CP, residues 132 - 158) to the serine protease domain (residues 159 - 411). Although direct molecular interactions with urokinase receptor and integrins have been extensively described, the function of single uPA domains is not completely understood. Because of the causal involvment of uPA in cancer invasion and metastasis, the blockade of uPA interactions and activity with specific inhibitors is of interest for novel strategies in cancer therapy. New inhibitors derived from the interdomain linker or "connecting peptide" are coming into focus. This review summarizes the recent findings on the uPA structure-function relationship and provides further information on existing inhibitors of uPA multiple functions.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.